CN111183127B - 大麻二酚的共晶 - Google Patents

大麻二酚的共晶 Download PDF

Info

Publication number
CN111183127B
CN111183127B CN201880053149.2A CN201880053149A CN111183127B CN 111183127 B CN111183127 B CN 111183127B CN 201880053149 A CN201880053149 A CN 201880053149A CN 111183127 B CN111183127 B CN 111183127B
Authority
CN
China
Prior art keywords
crystal
isopropenyl
methylcyclohex
diol
cbd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880053149.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN111183127A (zh
Inventor
A·C·康姆利
N·泰松
C·希门尼斯·冈萨雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nandia
Original Assignee
Nandia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nandia filed Critical Nandia
Publication of CN111183127A publication Critical patent/CN111183127A/zh
Application granted granted Critical
Publication of CN111183127B publication Critical patent/CN111183127B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/68—Purification; separation; Use of additives, e.g. for stabilisation
    • C07C37/70—Purification; separation; Use of additives, e.g. for stabilisation by physical treatment
    • C07C37/84—Purification; separation; Use of additives, e.g. for stabilisation by physical treatment by crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/17—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings containing other rings in addition to the six-membered aromatic rings, e.g. cyclohexylphenol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880053149.2A 2017-08-07 2018-08-06 大麻二酚的共晶 Active CN111183127B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382555 2017-08-07
EP17382555.5 2017-08-07
PCT/EP2018/071238 WO2019030158A1 (en) 2017-08-07 2018-08-06 CO-CRYSTAL OF 2 - [(1R, 6R) -6-ISOPROPENYL-3-METHYLCYCLOHEX-2-EN-1-YL] -5-PENTYLBENZENE-1,3-DIOL

Publications (2)

Publication Number Publication Date
CN111183127A CN111183127A (zh) 2020-05-19
CN111183127B true CN111183127B (zh) 2023-02-21

Family

ID=59677166

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880053149.2A Active CN111183127B (zh) 2017-08-07 2018-08-06 大麻二酚的共晶

Country Status (6)

Country Link
US (1) US11168047B2 (enExample)
EP (1) EP3665145A1 (enExample)
JP (1) JP7186460B2 (enExample)
CN (1) CN111183127B (enExample)
CA (1) CA3107566A1 (enExample)
WO (1) WO2019030158A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018383598B2 (en) 2017-12-11 2024-03-07 Artelo Biosciences, Inc. New solid forms of cannabidiol and uses thereof
US20230381134A1 (en) * 2020-01-03 2023-11-30 Purisys, Llc Cocrystals of cannabinoids
US20230183202A1 (en) * 2020-05-19 2023-06-15 Ebers Tech Inc. Tetrahydrococannabinolic acid cocrystals
CN111792982B (zh) * 2020-07-10 2024-05-14 云南农业大学 一种易于溶解的块状cbd晶型i及其制备方法
CN113004126B (zh) * 2021-03-05 2022-03-22 中国科学院上海药物研究所 羟基酪醇甜菜碱共晶，其制备方法及组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2393182A (en) * 2002-09-23 2004-03-24 Gw Pharma Ltd Substantially pure cannabidiol and a method of obtaining it from plant material

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2548281C (en) * 2003-12-09 2013-11-12 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
AU2006297300B2 (en) 2005-09-29 2012-05-10 Albany Molecular Research, Inc. Process for production of delta-9-tetrahydrocannabinol
ES2534900T3 (es) 2007-07-30 2015-04-30 Zynerba Pharmaceuticals, Inc. Profármacos de cannabidiol, composiciones que comprenden los profármacos de cannabidiol y métodos de uso de los mismos
EP2123626A1 (en) 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
AU2009345154A1 (en) * 2009-04-29 2011-12-22 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
EP2491933A1 (en) * 2009-10-23 2012-08-29 Astellas Pharma Inc. Pharmaceutical composition for oral administration
WO2012116349A2 (en) * 2011-02-26 2012-08-30 Amplio Pharma, Llc Novel cocrystals of ezetimibe
EP2842933B1 (de) 2013-09-03 2015-07-29 Symrise AG Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung
US10226442B2 (en) * 2017-07-10 2019-03-12 Syneurx International (Taiwan) Corp. Lithium salts of N-substituted glycine compounds and uses thereof
AU2018383598B2 (en) 2017-12-11 2024-03-07 Artelo Biosciences, Inc. New solid forms of cannabidiol and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2393182A (en) * 2002-09-23 2004-03-24 Gw Pharma Ltd Substantially pure cannabidiol and a method of obtaining it from plant material

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Impact of pharmaceutical cocrystals: the effects on drug pharmacokinetics;Ning Shan等;《Expert Opin. Drug Metab. Toxicol》;20141231;第10卷(第9期);1255-1271 *

Also Published As

Publication number Publication date
JP7186460B2 (ja) 2022-12-09
CN111183127A (zh) 2020-05-19
US11168047B2 (en) 2021-11-09
WO2019030158A1 (en) 2019-02-14
EP3665145A1 (en) 2020-06-17
US20200369586A1 (en) 2020-11-26
JP2020529450A (ja) 2020-10-08
CA3107566A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
CN111183127B (zh) 大麻二酚的共晶
CN113905730B (zh) 大麻素共晶体的固体组合物
JP6591944B2 (ja) ナルメフェン塩酸塩二水和物
CA3019890A1 (en) Bioenzymatic synthesis of tetrahydrocannabivarin (thc-v), cannabinol (cbn), and cannabivarin (cbv) and their use as therapeutic agents
WO2011043954A1 (en) Novel trpa1 antagonists
WO2005075474A1 (ja) コハク酸ソリフェナシン含有組成物
KR20180040694A (ko) 이브루티닙의 결정형 및 그 제조 방법
CN108727347B (zh) 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
US11584715B2 (en) Crystalline form of sofpironium bromide and preparation method thereof
WO2005087231A1 (ja) ソリフェナシン含有組成物
US12338223B2 (en) Methods of preparing synthetic cannabinol and homologs thereof
US20230381134A1 (en) Cocrystals of cannabinoids
CN110627599B (zh) 氘代丁基苯酞类化合物及其用途
KR20130026414A (ko) 3-(치환된 디히드로이소인돌리논-2-일)-2,6-디옥소피페리딘의 다형체 및 이의 약학적 조성물
JPWO2007105711A1 (ja) アダマンチル（モノ又はポリ）酢酸の製造方法、及びこれを用いたアダマンチル（モノ又はポリ）エタノールの製造方法
US10800801B2 (en) Crystalline platinum-based compounds
EP2739610B1 (en) Process for the manufacture of ivabradine and of intermediates of synthesis thereof
CN106336363A (zh) 一种沙芬酰胺甲磺酸盐晶型c及其制备方法
HU228820B1 (en) Process for the preparation of distrontium ranelate
Chavakula et al. Synthesis and spectral characterization of potential impurities of tiaprofenic acid
CA2797350A1 (en) Co-crystal intermediates of rosuvastatin and methods of using same
HK40068368B (zh) 索吡溴铵的晶型及其制备方法
FR2931823A1 (fr) Sel de fumarate du 1,4-diazabicyclo°3.2.2!nonane-carboxylate de 4-bromophenyle, ses formes cristallines, leur preparation et leur utilisation en therapeutique
HK1261156A1 (en) Crystals of novel hydroxamic acid derivative, method for producing same, and pharmaceutical composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant